Program Director, Multiple Sclerosis Fellowship; Neurologist, The Ohio State Neurological Institute
November 27, 2021
Article
As the field of MS care turns its sights on addressing progressive disease, the need for more biomarkers of disease activity and therapeutic target engagement is perhaps greater than ever.
Cognitive Functioning and Motor Difficulties Identified in Spinal Muscular Atrophy Type 3
Background Factors Drive Elevated Risk of Neonatal Seizures, Epilepsy in Children of Mothers on SSRI/SNRIs
Advocacy’s Part in the Progress in ALS: Matthew B. Harms, MD
This Week on NeurologyLive® — May 16, 2022